Drug Trial Radar · NCT06690775
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Nov 20, 2024
Primary completion
Oct 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- TORL Biotherapeutics, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- Nov 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Conditions
- Epithelial Ovarian Cancer
- Primary Peritoneal
- Fallopian Tube Cancer
- Endometrioid Ovarian Cancer
Interventions
TORL-1-23Drug
2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.
TORL-1-23Drug
3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
TORL-1-23Drug
3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
Pegfilgrastim (drug)Drug
6.0 mg subcutaneous injection on Day 4 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced PROC expressing CLDN6Time frame: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
Locations
81 sites in 13 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
TMC HealthCare
Tucson, Arizona
City of Hope National Medical Center
Duarte, California
Providence St. Jude Medical Center
Fullerton, California
UCLA - JCCC Clinical Research Unit
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
SCRI - Sansum Clinic
Santa Barbara, California
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado
Smilow Cancer Hospital at Yale - New Haven
New Haven, Connecticut
Mayo Clinic Florida
Jacksonville, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
SCRI - Maryland Oncology Hematology, P.A.
Annapolis, Maryland
Massachusetts General Hospital
Boston, Massachusetts
SCRI - Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
Rutgers Cancer Institute
New Brunswick, New Jersey
Duke Cancer Center
Durham, North Carolina
The James Cancer Hospital and Solove Research Institute - Ohio State University
Columbus, Ohio
Stephenson Cancer Center at the University of Oklahoma
Oklahoma City, Oklahoma
SCRI - Northwest Cancer Specialists, P.C.
Portland, Oregon
SCRI - Alliance Cancer Specialists, PC
Doylestown, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
SCRI - Texas Oncology
Fort Worth, Texas
SCRI - Virginia Oncology Associates
Norfolk, Virginia
Providence Swedish Cancer Institute
Seattle, Washington
Monash Medical Centre
Clayton, Melbourne, Australia
Blacktown Hospital
Blacktown, New South Wales, Australia
Icon Cancer Centre Chermside
Chermside, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Linear Clinical Research
Perth, Western Australia, Australia
Medizinische Universitat Landeskrankenhaus Graz
Graz, Styria, Austria
Universitatsklinik Innsbruck
Innsbruck, Tyrol, Austria
Ordensklinikum Linz
Linz, Upper Austria, Austria
Antwerp University Hospital (UZA)
Edegem, Antwerp, Belgium
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Brussels Capital, Belgium
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.